Belgian Luxury Stock News

Proximus PLC has reported past first-quarter 2026 results showing sales of €1,510 million and revenue of €1,525 million, with net income of €124 million and basic earnings per share from continuing operations of €0.38, all lower than the same period a year earlier. This broad-based decline across sales, revenue and earnings measures raises questions about how effectively Proximus’s existing efficiency programs and investment plans are offsetting current pressures on its business. We’ll now...

It looks like KBC Group NV ( EBR:KBC ) is about to go ex-dividend in the next 4 days. The ex-dividend date is commonly...

Recent share performance and business context VGP (ENXTBR:VGP) has drawn investor attention after the stock declined 10.2% over the past day, extending falls of 5.6% over the past week and 11.3% over the past month. Those moves come as the €2.21b logistics and semi industrial real estate company, headquartered in Antwerp, continues to generate revenue of €191.99m and net income of €290.44m. This performance is partly supported by its renewable energy activities. See our latest analysis for...

Viohalco (ENXTBR:VIO) drew attention after its stock climbed 13.55% in after-hours trading on EURONEXT on 7 May, as investors focused on its aluminium, copper, cables, and steel operations. See our latest analysis for Viohalco. That after hours jump adds to strong recent momentum, with a 7 day share price return of 16.45% and a 30 day share price return of 23.60%. The 1 year total shareholder return of 218.26% and 5 year total shareholder return of 288.09% underline how sentiment has shifted...

Syensqo SA/NV ( EBR:SYENS ) is about to trade ex-dividend in the next 2 days. Typically, the ex-dividend date is two...

NV Bekaert SA ( EBR:BEKB ) is about to trade ex-dividend in the next 3 days. The ex-dividend date generally occurs two...

argenx (ENXTBR:ARGX) appointed Karen Massey as CEO, and co founder Tim Van Hauwermeiren moved to Chairperson. The company reported strong Q1 results, with accelerating VYVGART sales highlighted as a key driver. An FDA decision on a potential Vyvgart label expansion in seronegative generalized myasthenia gravis is expected soon. argenx focuses on antibody based therapies for autoimmune diseases, with VYVGART already a central product in its portfolio. For investors watching the immunology...

Syensqo cancelled a significant number of shares it had repurchased as part of its ongoing buyback program. The move changes the total number of outstanding shares and voting rights for ENXTBR:SYENS. The action forms part of a broader capital management approach that affects how ownership is distributed across shareholders. For investors watching ENXTBR:SYENS, the cancellation of repurchased shares directly alters the share count that sits behind the current €57.3 price. Recent performance...

As you might know, Anheuser-Busch InBev SA/NV ( EBR:ABI ) just kicked off its latest first-quarter results with some...

Investors may be wondering whether argenx at €678.60 is offering fair value or carrying a premium, particularly after its strong long term share price record. The stock has returned 2.0% over the last 7 days, 4.9% over the last 30 days, a 6.2% decline year to date and 19.8% over the last year, with longer term returns of 86.7% over 3 years and 220.1% over 5 years. Recent coverage around argenx has focused on its position in the biotech sector and investor debate around how much future growth...

Why Xior’s latest quarterly results matter for investors Xior Student Housing (ENXTBR:XIOR) has drawn fresh attention after reporting first quarter 2026 earnings, with sales of €48.67 million and net income of €48.6 million, compared with €43.88 million and €41.95 million a year earlier. See our latest analysis for Xior Student Housing. Despite the stronger first quarter figures, the share price is at €27.6, with a 1 day share price return of 0.91% but a 1 year total shareholder return of...

At its 29 April 2026 shareholder meeting, Anheuser-Busch InBev approved a €1.15 gross total dividend for 2025 and refreshed its board, appointing Fabrizio Freda and Miguel Patricio as directors alongside new Restricted Share Directors. Coupled with a planned US$600.00 million investment in U.S. manufacturing and workforce training, these moves highlight AB InBev’s focus on strengthening operations and supporting shareholder returns. Next, we’ll examine how AB InBev’s newly approved...

ageas (ENXTBR:AGS) has completed the acquisition of the remaining stake in AG Insurance, consolidating full ownership of its Belgian insurance business. The company has issued new and treasury shares to BNP Paribas Cardif, increasing its outstanding share capital and reshaping its shareholder base. ageas is accelerating expansion in India, aiming for a top 10 position through acquisitions and deeper bancassurance partnerships. For investors watching ENXTBR:AGS, these moves come as the share...

Campine NV's ( EBR:CAMB ) robust earnings report didn't manage to move the market for its stock. Our analysis suggests...

As European markets face heightened geopolitical tensions and economic uncertainties, traditionally defensive sectors such as utilities and telecoms have shown resilience, with the pan-European STOXX Europe 600 Index recently experiencing a decline. In this environment, dividend stocks can offer a measure of stability and potential income for investors seeking to navigate these challenging times.

UCB (ENXTBR:UCB) is presenting new clinical and real-world data at the American Academy of Neurology Annual Meeting. The updates cover epileptic encephalopathies, prolonged seizures, and generalized myasthenia gravis. Key datasets focus on fenfluramine in Dravet and Lennox Gastaut syndromes and on zilucoplan and rozanolixizumab in myasthenia gravis. Additional findings address patient and caregiver quality of life, healthcare resource use, and treatment patterns. For investors following...

BGL BNP Paribas (ENXTBR:009789111) has released its full year 2025 results, reporting net income of €514.5 million compared to €477.9 million a year earlier. This provides investors with fresh data to reassess the stock. See our latest analysis for BGL BNP Paribas. The share price is currently €89.0, and the flat short-term share price returns sit alongside a 1-year total shareholder return of 0.00%. This suggests recent earnings news may not yet have shifted market expectations in a clear...

Solvac S.A.'s ( EBR:SOLV ) solid earnings announcement recently didn't do much to the stock price. Our analysis...

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...

Onward Medical (ENXTBR:ONWD) has reported its FY 2025 first half with revenue of €1.2 million, a basic EPS loss of €0.47, and net income loss of €21.2 million, setting a clear tone for another year focused on growth over profitability. The company has seen revenue move from €0.2 million in the first half of 2024 to €1.5 million in the second half of 2024 and €1.2 million in the first half of 2025. Basic EPS has shifted between losses of €0.53, €0.32, and €0.47 over the same periods,...

As European markets navigate the complexities of Middle East conflicts and energy price volatility, indices like the STOXX Europe 600 have shown modest gains, reflecting a cautious optimism amidst geopolitical uncertainties. In these fluctuating times, dividend stocks can offer investors a measure of stability and potential income, making them an appealing consideration for those looking to balance risk with consistent returns.

SCR-Sibelco N.V.'s ( EBR:094426466 ) healthy profit numbers didn't contain any surprises for investors. However the...

Sofina Société Anonyme (ENXTBR:SOF) opened FY 2025 with a weak first half, reporting a loss as basic EPS swung to €11.87 and total revenue came in at a loss of €358.9 million. This comes against a backdrop where the trailing twelve months still show positive EPS of €12.48 and revenue of €486.1 million. Over the past year, the company has seen total revenue move from €587.1 million in 2024 H1 to €844.98 million in 2024 H2 and EPS shift from €16.59 to €24.29 in the same periods, before the...

The European market has recently faced challenges, with the pan-European STOXX Europe 600 Index declining by 3.79% amid heightened geopolitical tensions and soaring energy costs, prompting caution from the European Central Bank regarding inflation risks. In this environment of uncertainty, high-growth tech stocks in Europe are gaining attention for their potential to offer resilience and innovation-driven growth, making them an intriguing focus for investors seeking opportunities in a...